Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Stott, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Quality driven management of tablet-treated type 2 diabetes — potential increases in GP practice prescribing costs

Peter Stott

Tadworth Medical Centre, Troy Close, Tadworth, Surrey, KT20 5JE, UK, Peter.Stott{at}BTInternet.com

A prospective audit was undertaken to characterise Ametabolic control, risk-factor profiles and costs of pharmaceutical agents required to achieve quality target measures in 100 type 2 diabetic patients attending a diabetic clinic in UK general practice. Despite reasonable glycaemic control, the coronary risk of these patients was high due to age, diabetes and dyslipidaemia. It proved impossible to quantify coronary risk for many older patients exactly since existing scales do not apply to patients aged over 75 years. The extra cost of initiating new treatments to modify coronary heart disease (CHD) risk for an average patient with type 2 diabetes was estimated to be £400—£860 (average £633) per annum. The treatment costs of instituting treatment to achieve quality measures should be considered when new quality standards are introduced. Without this investment the long-term costs of managing the complications of diabetes will be much higher.

Key Words: diabetes • quality • NSF • guidelines • prescribing • costs.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 1, 64-68 (2003)
DOI: 10.1177/14746514030030011101
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?